- Home
- ASG vs VALN Comparison
ASG vs VALN Comparison
Compare ASG & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- VALN
- Stock Information
- Founded
- ASG 1986
- VALN 2012
- Country
- ASG United States
- VALN France
- Employees
- ASG N/A
- VALN N/A
- Industry
- ASG Investment Managers
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASG Finance
- VALN Health Care
- Exchange
- ASG Nasdaq
- VALN Nasdaq
- Market Cap
- ASG 345.3M
- VALN 354.8M
- IPO Year
- ASG N/A
- VALN 2021
- Fundamental
- Price
- ASG $5.93
- VALN $4.71
- Analyst Decision
- ASG
- VALN Strong Buy
- Analyst Count
- ASG 0
- VALN 2
- Target Price
- ASG N/A
- VALN $18.50
- AVG Volume (30 Days)
- ASG 324.3K
- VALN 68.4K
- Earning Date
- ASG 01-01-0001
- VALN 11-07-2024
- Dividend Yield
- ASG 8.09%
- VALN N/A
- EPS Growth
- ASG N/A
- VALN N/A
- EPS
- ASG N/A
- VALN N/A
- Revenue
- ASG N/A
- VALN $176,817,979.00
- Revenue This Year
- ASG N/A
- VALN $24.66
- Revenue Next Year
- ASG N/A
- VALN $9.67
- P/E Ratio
- ASG N/A
- VALN N/A
- Revenue Growth
- ASG N/A
- VALN N/A
- 52 Week Low
- ASG $4.47
- VALN $3.62
- 52 Week High
- ASG $5.71
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- ASG 61.44
- VALN 59.69
- Support Level
- ASG $5.52
- VALN $4.22
- Resistance Level
- ASG $5.80
- VALN $4.51
- Average True Range (ATR)
- ASG 0.09
- VALN 0.22
- MACD
- ASG 0.03
- VALN 0.02
- Stochastic Oscillator
- ASG 96.43
- VALN 85.17
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.